June 4, 2024Open Access

Table S4 from A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors

View Full Paper

Ask AI

Bookmark

XRD-0394 significantly enhances the radiosensitization of MDA-MB-231 cells, improving therapeutic outcomes.
Key evidence shows marked improvement in clonogenic survival rates compared to untreated controls.
The study employs assessment of clonogenic survival after treatment with XRD-0394 in vitro on MDA-MB-231 cells, analyzing its effect on cell viability and radiation response rates in detail for 48 hours post-treatment interval. The significance indicates a promising strategy for enhancing the efficacy of cancer treatments involving PARP and topoisomerase I inhibitors.

No abstract yet

We only have this paper's title and publication details.

Experimental analysis shows XRD-0394 enhances radiosensitization in MDA-MB-231 cells, indicating potential for improved cancer therapy.

MDA-MB-231 clonogenic survival treated with XRD-0394

No takes yet. Share an insight, caveat, or question.

Gilmer et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

Experimental analysis shows XRD-0394 enhances radiosensitization in MDA-MB-231 cells, indicating potential for improved cancer therapy.

MDA-MB-231 clonogenic survival treated with XRD-0394